iX Biopharma Balance Sheet Health
Financial Health criteria checks 3/6
iX Biopharma has a total shareholder equity of SGD7.7M and total debt of SGD5.3M, which brings its debt-to-equity ratio to 68.7%. Its total assets and total liabilities are SGD18.3M and SGD10.7M respectively.
Key information
68.7%
Debt to equity ratio
S$5.26m
Debt
| Interest coverage ratio | n/a |
| Cash | S$6.09m |
| Equity | S$7.66m |
| Total liabilities | S$10.65m |
| Total assets | S$18.31m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 42C's short term assets (SGD9.8M) exceed its short term liabilities (SGD7.1M).
Long Term Liabilities: 42C's short term assets (SGD9.8M) exceed its long term liabilities (SGD3.6M).
Debt to Equity History and Analysis
Debt Level: 42C has more cash than its total debt.
Reducing Debt: 42C's debt to equity ratio has increased from 27.3% to 68.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 42C has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 42C has less than a year of cash runway if free cash flow continues to grow at historical rates of 16.9% each year.